PepGen Inc.
PEPG evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $209.2M
- Lead Asset:
- pgn-edo51 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for PEPG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PEPG
PepGen Inc. (PEPG) is a pre-revenue biotech company focused on developing PGN-EDODM1 for myotonic dystrophy type 1 (DM1), having discontinued its Duchenne muscular dystrophy (DMD) program in 2025.
Key risk: Single-product pipeline
BioSniper Score
Based on 4 of 6 signals
Market Cap
$209.2M
Cash Runway
—
Lead Asset
pgn-edo51 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials for PepGen Inc..
PepGen Inc. (PEPG) is a pre-revenue biotech company focused on developing PGN-EDODM1 for myotonic dystrophy type 1 (DM1), having discontinued its Duchenne muscular dystrophy (DMD) program in 2025.
- Cash, cash equivalents, and marketable securities of $117.2 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Net loss of $17.8 million for the six months ended June 30, 2026 (latest reported financials as of 2026-06-30) [sec].
- Accumulated deficit of $396.7 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Phase 2 FREEDOM2 trial for PGN-EDODM1 ongoing; top-line data from the 2 mg/kg and 5 mg/kg cohorts expected in the first half of 2027 [sec_mda · as of 2026-08-06].
- Discontinued development of PGN-EDO51 and substantially completed wind-down of DMD-related R&D activities as of May 28, 2025 [sec_mda · as of 2026-08-06].
What works
- PGN-EDODM1 has received FDA Orphan Drug and Fast Track designations and EMA orphan medicinal product designation, which may expedite development and regulatory review [sec_mda · as of 2026-08-06].
- The company raised $107.6 million in net proceeds from a September 2025 public offering, bolstering its cash position [sec_mda · as of 2026-05-12].
- Cash runway is projected into the fourth quarter of 2027 based on currently planned operations [sec_mda · as of 2026-08-06].
What to weigh
- PepGen has incurred operating losses every year since inception, with a net loss of $17.8 million in the first half of 2026 and an accumulated deficit of $396.7 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- The company is pre-revenue and does not expect product sales for at least several more years, if ever [sec_mda · as of 2026-08-06].
- The discontinuation of the DMD program (PGN-EDO51) narrows the pipeline to a single lead candidate (PGN-EDODM1) for DM1, increasing program risk [sec_mda · as of 2026-08-06].
- Substantial additional funding will be needed to complete development and potential commercialization; failure to raise funds could force delays or discontinuation [sec_mda · as of 2026-03-04].
From the filings
Quoted directly from source documents.
Cash position and runway
“had cash, cash equivalents, and marketable securities of $117.2 million. We believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our currently planned operations into the fourth quarter of 2027.”
SEC MD&A · August 6, 2026
Discontinuation of DMD program
“On May 28, 2025, we announced that we decided to voluntarily discontinue development of PGN-EDO51 and have recently substantially completed the wind-down of DMD-related research and development activities.”
SEC MD&A · August 6, 2026
Accumulated deficit
“As of June 30, 2026, we had an accumulated deficit of $396.7 million.”
SEC MD&A · August 6, 2026
Regulatory designations for PGN-EDODM1
“The FDA has granted both orphan drug designation and Fast Track designation for PGN-EDODM1 for the treatment of DM1 and the EMA has also granted orphan medicinal product designation to PGN-EDODM1.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2023-12-12 · Phase 1 Start (FREEDOM-DM1) — Phase 1 placebo-controlled study of PGN-EDODM1 in adults with DM1 initiated.
- 2024-01-03 · Phase 2 Start (CONNECT1-EDO51) — Phase 2 open-label study of PGN-EDO51 in DMD patients amenable to exon 51-skipping (program later discontinued).
- 2024-12-10 · Phase 2 Start (FREEDOM2-DM1) — Phase 2 randomized, double-blind, placebo-controlled study of PGN-EDODM1 in DM1 patients.
- 2024-12-17 · Phase 2 Start (second study) — Additional Phase 2 study initiated (details not fully specified in chunks).
Risks & what to watch (4)›
Key risks
- Single-product pipeline — With DMD program discontinued, PepGen relies solely on PGN-EDODM1 for DM1; failure would leave no pipeline [sec_mda · as of 2026-08-06].
- Pre-revenue and cash burn — No product sales expected for years; net loss of $17.8M in H1 2026 and accumulated deficit of $396.7M as of June 30, 2026 [sec].
- Need for additional funding — Substantial capital required for Phase 3 and commercialization; failure to raise could force delays or shutdown [sec_mda · as of 2026-03-04].
- Clinical trial execution risk — Phase 2 FREEDOM2 data not expected until H1 2027; delays or negative results would harm prospects [sec_mda · as of 2026-08-06].
What to watch
- Top-line data from the 2 mg/kg and 5 mg/kg cohorts of the Phase 2 FREEDOM2 trial, expected in the first half of 2027 [sec_mda · as of 2026-08-06].
- Cash runway updates; management projects funding into Q4 2027, but actual burn rate may vary [sec_mda · as of 2026-08-06].
- Any new financing or partnership activities given the need for substantial additional capital [sec_mda · as of 2026-03-04].
- Regulatory milestones for PGN-EDODM1, including potential Phase 3 trial design and FDA/EMA interactions [sec_mda · as of 2026-08-06].
Sources: Catalysts · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run PepGen Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PepGen Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.18 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 6.4%
- Days to cover
- 1.7
- Shares short
- 3,438,459
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PEPG short interestGovernance
Frequently asked questions
What is the AI investment thesis for PepGen Inc.?
PepGen Inc. (PEPG) is a pre-revenue biotech company focused on developing PGN-EDODM1 for myotonic dystrophy type 1 (DM1), having discontinued its Duchenne muscular dystrophy (DMD) program in 2025.
What is PepGen Inc.'s lead drug candidate?
PepGen Inc.'s most advanced tracked candidate is pgn-edo51 (Phase 2) for Duchenne Muscular Dystrophy.
Who is the CEO of PepGen Inc.?
Dr. James G. McArthur Ph.D. is the chief executive officer of PepGen Inc. (PEPG).
Where is PepGen Inc. headquartered?
PepGen Inc. (PEPG) is headquartered in Boston, MA, United States.
What therapeutic areas does PepGen Inc. focus on?
PepGen Inc. develops therapies across Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.